Military Makeover

We’re honored to support Army Staff Sergeant Matthew Mitchell and all Veterans by participating in Military Makeover with Montel®. 

Mark your calendars! CVB’s CEO & President Magali Haas, MD, PhD joins Veteran Matthew Mitchell to discuss traumatic brain injury research in Episode 2 airing June 2 and June 8 on Lifetime TV at 7:30 am ET/PT and online

CVB is raising funds to help provide solutions for TBI and PTSD for Veterans. 

Can we count on you to help? Donate today – 100% of your donation will go toward advancing research.

Cohen Veterans Bioscience

“The effects of Traumatic Brain Injury should never be underestimated and I fully support the advancements in science Cohen Veterans Bioscience is leading.”

– U.S. Army Staff Sergeant Matthew Mitchell

While on deployment in Iraq, Matthew’s vehicle drove over an improvised explosive device (IED). The intense explosion and its aftermath left him with numerous injuries and PTSD. Matthew was awarded a Purple Heart for his service and sacrifice, but still lives with the physical and emotional scars from the traumatic event.

U.S. Army Staff Sergeant Matthew Mitchell and CVB CEO and President Dr. Magali Haas
U.S. Army Staff Sergeant Matthew Mitchell and CVB CEO & President Dr. Magali Haas
Military Makeover

Watch Episode 2:

Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email

Donate to Cohen Veterans Bioscience

Get the latest updates in PTSD & TBI Research

I would like updates on:

By submitting this form, you are consenting to email communications from CVB.

About Cohen Veterans Bioscience

We’re leading a new approach in research, diagnosis, treatments and advocacy for PTSD and TBI.

Cohen Veterans Bioscience is a non-profit 501(c)(3) biomedical research and technology organization dedicated to advancing brain health by fast-tracking precision diagnostics and tailored therapeutics. We are leading the way to cure “invisible wounds” for the millions of veterans, service members, first responders, and civilians who suffer from trauma-related conditions.

Our goal is to advance tailored treatments for PTSD and TBI so that a clinician can target the right treatment to the right person at the time when they need help most.